Screener
Viridian Therapeutics, Inc. VRDN Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Viridian Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The source filing: Viridian Therapeutics, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 7:31 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001590750-26-000018
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Accounts payable | (574) | 6,396 |
| Accrued and other liabilities | (17,573) | (9,721) |
| Other liabilities | (342) | (144) |
| Net cash used in operating activities | (224,978) | (168,026) |
| Cash flows from investing activities: | ||
| Purchases of marketable securities | (469,975) | (126,998) |
| Maturities of marketable securities | 317,408 | 302,906 |
| Purchase of property and equipment | (1,329) | (128) |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Viridian Therapeutics, Inc.'s operating cash flow?
- Viridian Therapeutics, Inc. (VRDN) reported operating cash flow of -$105.32M in Q2 2026.
- How has Viridian Therapeutics, Inc.'s operating cash flow changed year-over-year?
- Viridian Therapeutics, Inc.'s operating cash flow decreased by 39.7% year-over-year, from -$75.37M to -$105.32M.
- What is the long-term trend for Viridian Therapeutics, Inc.'s operating cash flow?
- Over 4 years (2021 to 2025), Viridian Therapeutics, Inc.'s operating cash flow has grown at a 50.0% compound annual growth rate (CAGR), from -$54.58M to -$276.39M.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.
Ask your AI about Viridian Therapeutics, Inc.'s operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude